Abstract
The importance of medical devices as a source of infection has been increasingly appreciated. Candida spp. are responsible for a significantly increasing number of device-related infections, particularly those involving the bloodstream and urinary tract. A wide range of devices may be colonized by Candida spp., including central venous catheters, cardiac devices, and knee and hip prostheses. Medical device infections invariably require antifungal therapy and, in many cases, device removal, with associated hazards to some patients. Currently recommended treatments include amphotericin B formulations, azoles and echinocandins. The echinocandins, with efficacy against Candida biofilms, may have a role in the future in improved lock therapy for the treatment of device-associated candidal infections.
Similar content being viewed by others
References
Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004 Apr; 17(2): 255–67
Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007 Jan; 20(1): 133–63
Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007 Jun; 45(6): 1843–50
Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003 Nov; 3(11): 685–702
Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intra-vascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(1): 1–45
Walsh TJ, Rex JH. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis 2002 Mar; 34(5): 600–2
Raad I, Hanna H, Maki D. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis 2007 Oct; 7(10): 645–57
Pappas PG, Kauffman CA, Andes D, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009 Mar 1; 48(5): 503–35
Pierrotti LC, Baddour LM. Fungal endocarditis, 1995–2000. Chest 2002 Jul; 122(1): 302–10
Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007 May; 49(18): 1851–9
Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect Dis 2006 Jul; 6(7): 426–37
Kauffman CA. Candiduria. Clin Infect Dis 2005 Sep; 41 Suppl. 6: S371–6
Sánchez-Portocarrero J, Martín-Rabadán P, Saldaña CJ, et al. Candida cerebrospinal fluid shunt infection: report of two new cases and review of the literature. Diagn Microbiol Infect Dis 1994 Sep; 20(1): 33–40
Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995 Sep; 39(9): 2128–31
Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002 Jun; 46(6): 1773–80
Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002 Nov; 46(11): 3634–6
Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspo-fungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008 Jul; 62(1): 153–5
Katragkou A, Chatzimoschou A, Simitsopoulou M, et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 2008; 52: 357–60
Peman J, Canton E, Valentin A. Actividad de la anidula-fungina sobra biopelìculas de Candida. Rev Iberoram Micol 2008; 25: 124–8
Acknowledgements
The author thanks Andrea Bothwell of Wolters Kluwer Pharma Solutions who provided assistance with English language editing. This assistance was funded by Pfizer.
Roberto Cauda has attended advisory boards, or has been a consultant, for GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Boehringer-Ingelheim, Pfizer, Abbott, Merck Sharp & Dohme and Wyeth.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cauda, R. Candidaemia in Patients with an Inserted Medical Device. Drugs 69 (Suppl 1), 33–38 (2009). https://doi.org/10.2165/11315520-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11315520-000000000-00000